CardioLife

CardioLife’s Universal Console Architecture is a single control and monitoring platform running three devices: EasyFlow ECMO for acute stabilisation, an external VAD for bridge support, and the EasyHeart implantable LVAD for long-term therapy. One console, one training pathway, one service contract across the full pathway of care.

CardioLife sells devices to hospitals, with recurring revenue from consumables, implants, and service. It manufactures in Australia and India for price-sensitive markets.

Hospitals treating advanced heart failure must buy, maintain and train staff on separate systems for Extracorporeal Membrane Oxygenation (ECMO), temporary Ventricular Assist Device (VAD) and implantable Left Ventricular Assist Device (LVAD). Each console carries its own capital cost, service contract and learning curve. At roughly US$100,000 per LVAD, most hospitals outside high-income markets cannot justify the outlay.

Cardiac units at tertiary hospitals performing mechanical circulatory support — initially KIMS Hospital Group (India) and St Vincent’s Hospital Sydney, then Asia-Pacific private hospital networks.

• AU$25M raised (Series B), incl. AU$5M AMTZ
• Pre-clinical implants completed at Victor Chang and PIRL Adelaide
• Factory under construction at AMTZ; 25 Sydney staff